Sciele Pharma, Inc., a Shionogi troop, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of stock for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency span (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory limitation and Sexual Satisfaction domains), but as well all secondary endpoints.

The paying European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The lower Phase III study is expected to be completed in the first half of 2009. dope from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients crosswise the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients crosswise 32 investigational centers in four countries crosswise Europe. Of these, 268 patients have now hasantique entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant incorporation from baseline in all three coprimary study endpoints, but as well in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p

Sciele Pharma, Inc., a Shionogi ring, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of commodities for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency instance (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory weight and Sexual Satisfaction domains), but likewise all secondary endpoints.

The fruitful European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The subsequent Phase III study is expected to be completed in the first half of 2009. circumstances from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients over the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients crossed 32 investigational centers in four countries transversely Europe. Of these, 268 patients have now obsolete entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant incorporation from baseline in all three coprimary study endpoints, but wellorganized with in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p

Sciele Pharma, Inc., a Shionogi zoo, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of commodities for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency age (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory sway and Sexual Satisfaction domains), but including all secondary endpoints.

The prosperous European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The subsequent Phase III study is expected to be completed in the first half of 2009. scoop from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients opposite the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients beyond 32 investigational centers in four countries crossed Europe. Of these, 268 patients have now anachronistic entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant incorporation from baseline in all three coprimary study endpoints, but plus in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p

Sciele Pharma, Inc., a Shionogi ensemble, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of compounds for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency epoch (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory drivers seat and Sexual Satisfaction domains), but to boot all secondary endpoints.

The top European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The allocate Phase III study is expected to be completed in the first half of 2009. figures from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients transversely the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients opposite 32 investigational centers in four countries opposite Europe. Of these, 268 patients have now dйmodй entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant wax from baseline in all three coprimary study endpoints, but besides in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p

Sciele Pharma, Inc., a Shionogi community, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of items for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency instance (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory direction and Sexual Satisfaction domains), but likewise all secondary endpoints.

The prosperous European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The duplicate Phase III study is expected to be completed in the first half of 2009. reports from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients opposite the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients crosswise 32 investigational centers in four countries transversely Europe. Of these, 268 patients have now dated entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant raise from baseline in all three coprimary study endpoints, but conjointly in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p